Retracted: Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia
Retraction(s) for this article
-
Retraction: ‘Effect of blonanserin on cognitive function in antipsychotic-naïve first-episode schizophrenia’
- Tomomi Tenjin,
- Seiya Miyamoto,
- Nobumi Miyake,
- Shin Ogino,
- Rei Kitajima,
- Kazuaki Ojima,
- Jun Arai,
- Haruki Teramoto,
- Sachiko Tsukahara,
- Yukie Ito,
- Masanori Tadokoro,
- Kiriko Anai,
- Yasuyuki Funamoto,
- Yasuhiro Kaneda,
- Tomiki Sumiyoshi,
- Noboru Yamaguchi,
- Volume 32Issue 3Human Psychopharmacology: Clinical and Experimental
- First Published online: June 1, 2017
Corresponding Author
Tomomi Tenjin
- [email protected]
- +81 44 977 8111 | Fax: +81 44 976 3341
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
T. Tenjin, MD, Department of Neuropsychiatry, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. Tel: +81 44 977 8111; Fax: +81 44 976 3341. E-mail: [email protected]Search for more papers by this authorSeiya Miyamoto
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorNobumi Miyake
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorShin Ogino
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorRei Kitajima
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorKazuaki Ojima
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorJun Arai
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorHaruki Teramoto
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorSachiko Tsukahara
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorYukie Ito
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorMasanori Tadokoro
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorKiriko Anai
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorYasuyuki Funamoto
Department of Psychiatry, Ofuji Hospital, Fuji, Shizuoka, Japan
Search for more papers by this authorYasuhiro Kaneda
Department of Psychiatry, Iwaki Clinic, Anan, Tokushima, Japan
Search for more papers by this authorTomiki Sumiyoshi
Department of Neuropsychiatry, University of Toyama, Toyama, Japan
Search for more papers by this authorNoboru Yamaguchi
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorCorresponding Author
Tomomi Tenjin
- [email protected]
- +81 44 977 8111 | Fax: +81 44 976 3341
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
T. Tenjin, MD, Department of Neuropsychiatry, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan. Tel: +81 44 977 8111; Fax: +81 44 976 3341. E-mail: [email protected]Search for more papers by this authorSeiya Miyamoto
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorNobumi Miyake
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorShin Ogino
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorRei Kitajima
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorKazuaki Ojima
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorJun Arai
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorHaruki Teramoto
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorSachiko Tsukahara
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorYukie Ito
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorMasanori Tadokoro
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorKiriko Anai
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorYasuyuki Funamoto
Department of Psychiatry, Ofuji Hospital, Fuji, Shizuoka, Japan
Search for more papers by this authorYasuhiro Kaneda
Department of Psychiatry, Iwaki Clinic, Anan, Tokushima, Japan
Search for more papers by this authorTomiki Sumiyoshi
Department of Neuropsychiatry, University of Toyama, Toyama, Japan
Search for more papers by this authorNoboru Yamaguchi
Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
Search for more papers by this authorAbstract
Objective
The purpose of this study was to evaluate the effects of blonanserin, a novel antipsychotic, on cognitive function in first-episode schizophrenia.
Methods
Twenty-four antipsychotic-naïve patients with first-episode schizophrenia participated in the study. Blonanserin was given in an open-label design for 8 weeks. The Brief Assessment of Cognition in Schizophrenia—Japanese language version (BACS-J) was administered as the primary outcome measure at baseline and 8 weeks. Clinical evaluation included the Positive and Negative Syndrome Scale (PANSS), the Schizophrenia Quality of Life Scale—Japanese language version (SQLS-J), and the Clinical Global Impression—Severity of Illness Scale (CGI-S). To exclude the possibility of retest effects on the BACS-J, 10 age-matched patients with chronic schizophrenia treated with blonanserin were tested at baseline and after an 8-week interval.
Results
Twenty first-episode patients completed the study. Repeated measures analysis of covariance revealed a significant group-by-time interaction effect on the letter fluency task due to better performance in the first-episode group, but not in the control group. Main effect of time or group-by-time interaction effect on the Tower of London task was not significant; however, the first-episode group, but not the control group, showed substantial improvement with a moderate effect size. All items on the PANSS, SQLS-J, and CGI-S significantly improved after 8 weeks of treatment.
Conclusions
These results suggest that blonanserin improves some types of cognitive function associated with prefrontal cortical function. Copyright © 2012 John Wiley & Sons, Ltd.
REFERENCES
- Allen HA, Liddle PF, Frith CD. 1993. Negative features, retrieval processes and verbal fluency in schizophrenia. Br J Psychiatry 163: 769–775.
- American Psychiatric Association. 2000. Diagnostic Criteria from DSM-IV-TR. American Psychiatric Association: Washington, DC.
- Andersen R, Fagerlund B, Rasmussen H, et al. 2011. Cognitive effects of six months of treatment with quetiapine in antipsychotic-naive first-episode schizophrenia. Psychiatry Res 187: 49–54.
- Baker SC, Rogers RD, Owen AM, et al. 1996. Neural systems engaged by planning: a PET study of the Tower of London task. Neuropsychologia 34: 515–526.
- Bilder RM, Goldman RS, Robinson D, et al. 2000. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 157: 549–559.
- Birchwood M, Todd P, Jackson C. 1998. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 172: 53–59.
- Bokat CE, Goldberg TE. 2003. Letter and category fluency in schizophrenic patients: a meta-analysis. Schizophr Res 64: 73–78.
- Bozikas VP, Andreou C. 2011. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry 45: 93–108.
- Carpenter WT, Gold JM. 2002. Another view of therapy for cognition in schizophrenia. Biol Psychiatry 51: 969–971.
- Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, et al. 2009. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. J Clin Psychiatry 70: 717–729.
- Dagher A, Owen AM, Boecker H, et al. 1999. Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain 122(Pt 10): 1973–1987.
- Davidson M, Galderisi S, Weiser M, et al. 2009. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 166: 675–682.
- Deeks ED, Keating GM. 2010. Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs 24: 65–84.
- Fagerlund B, Mackeprang T, Gade A, et al. 2004. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 9: 364–374.
- Gold JM, Harvey PD. 1993. Cognitive deficits in schizophrenia. Psychiatr Clin North Am 16: 295–312.
- Goldberg TE, Goldman RS, Burdick KE, et al. 2007. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 64: 1115–1122.
- Goldberg TE, Keefe RS, Goldman RS, et al. 2010. Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies. Neuropsychopharmacology 35: 1053–1062.
- Gourovitch ML, Kirkby BS, Goldberg TE, et al. 2000. A comparison of rCBF patterns during letter and semantic fluency. Neuropsychology 14: 353–360.
- Green MF. 1996. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153: 321–330.
- Green MF, Kern RS, Braff DL, et al. 2000. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 26: 119–136.
- Guy W. 1976. Clinical Global Impression. US Department of Health and Human Services Publication (ADM): Rockville, MD.
- Hagger C, Buckley P, Kenny JT, et al. 1993. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702–712.
- Harvey PD, Keefe RS. 2001. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158: 176–184.
- Hill SK, Bishop JR, Palumbo D, et al. 2010. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 10: 43–57.
- Hill SK, Reilly JL, Harris MS, et al. 2009. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr Res 113: 167–175.
- Howanitz E, Cicalese C, Harvey PD. 2000. Verbal fluency and psychiatric symptoms in geriatric schizophrenia. Schizophr Res 42: 167–169.
- Inada T. 1996. Evaluation and diagnosis of drug-induced extrapyramidal symptoms: commentary on the DIEPSS and guide to its usage. G Yagi (ed.). Seiwa shoten: Tokyo.
- Kaneda Y, Imakura A, Fujii A, et al. 2002. Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res 113: 107–113.
- Kaneda Y, Sumiyoshi T, Keefe R, et al. 2007. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci 61: 602–609.
- Kaneda Y, Sumiyoshi T, Nakagome K, et al. 2008. The brief assessment of cognition in schizophrenia Japanese version (BACS-J). Seishin Igaku (Clinical Psychiatry) 50: 913–917.
- Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276.
- Keefe RS, Bilder RM, Davis SM, et al. 2007a. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 64: 633–647.
- Keefe RS, Malhotra AK, Meltzer HY, et al. 2008. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33: 1217–1228.
- Keefe RS, Seidman LJ, Christensen BK, et al. 2004. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161: 985–995.
- Keefe RSE, Silva SG, Perkins DO, et al. 1999. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25: 201–222.
- Keefe RS, Sweeney JA, Gu H, et al. 2007b. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1061–1071.
- Kinoshita T. 2008. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Japan-wide study). Jpn J Clin Psychopharmacol 11: 135–153.
- Kubota Y, Toichi M, Shimizu M, et al. 2005. Prefrontal activation during verbal fluency tests in schizophrenia—a near-infrared spectroscopy (NIRS) study. Schizophr Res 77: 65–73.
- Larsen TK, McGlashan TH, Moe LC. 1996. First-episode schizophrenia: I. Early course parameters. Schizophr Bull 22: 241–256.
- Lazeron RH, Rombouts SA, Machielsen WC, et al. 2000. Visualizing brain activation during planning: the tower of London test adapted for functional MR imaging. AJNR Am J Neuroradiol 21: 1407–1414.
- Liddle PF, Morris DL. 1991. Schizophrenic syndromes and frontal lobe performance. Br J Psychiatry 158: 340–345.
- MacDonald AW, 3rd, Carter CS, Kerns JG, et al. 2005. Specificity of prefrontal dysfunction and context processing deficits to schizophrenia in never-medicated patients with first-episode psychosis. Am J Psychiatry 162: 475–484.
- Mahurin RK, Velligan DI, Miller AL. 1998. Executive-frontal lobe cognitive dysfunction in schizophrenia: a symptom subtype analysis. Psychiatry Res 79: 139–149.
- Matsui M, Sumiyoshi T, Arai H, et al. 2008. Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 280–287.
- McEvoy JP, Hogarty GE, Steingard S. 1991. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48: 739–745.
- McEvoy JP, Lieberman JA, Perkins DO, et al. 2007. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 164: 1050–1060.
- Meltzer HY, Thompson PA, Lee MA, et al. 1996. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 14: 27S-33S.
- Mesholam-Gately RI, Giuliano AJ, Goff KP, et al. 2009. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23: 315–336.
- Mishara AL, Goldberg TE. 2004. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55: 1013–1022.
- Miura S. 2008. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with risperidone. Jpn J Clin Psychopharmacol 11: 297–314.
- Miyake N, Miyamoto S, Takeuchi A, et al. 2008. Effect of new-generation antipsychotic blonanserin on cognitive impairment in schizophrenia: A randomized double-blind comparison with risperidone. Jpn J Clin Psychopharmacol 11: 1329–1336.
- Miyamoto S, Fleischhacker WW, Lieberman JA. in press. Pharmacologic treatment of schizophrenia. In Comprehensive Care of Schizophrenia, 2nd edn, R Murray, JA Lieberman (eds). Oxford University Press: New York.
-
Miyamoto S,
Merrill DB,
Lieberman JA, et al. 2008. Antipsychotic drugs. In Psychiatry, 3rd edn, A Tasman, J Kay, JA Lieberman, et al. (eds). John Wiley & Sons: Chichester; 2161–2201.
10.1002/9780470515167.ch102 Google Scholar
- Morris RG, Ahmed S, Syed GM, et al. 1993. Neural correlates of planning ability: frontal lobe activation during the Tower of London test. Neuropsychologia 31: 1367–1378.
- Murasaki M. 2007a. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol 10: 2059–2079.
- Murasaki M. 2007b. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to determine safety and effectiveness in schizophrenic patients (Kanagawa Region Clinical Psychopharmacology Study Group). Jpn J Clin Psychopharmacol 10: 2241–2257.
- Noda Y, Kurumiya S, Miura Y, et al. 1993. Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and/or adverse side-effects. J Pharmacol Exp Ther 265: 745–751.
- Ogino S, Miyamoto S, Tenjin T, et al. 2011. Effects of discontinuation of long-term biperiden use on cognitive function and quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 35: 78–83.
- Ohoyama K, Yamamura S, Hamaguchi T, et al. 2011. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol 653: 47–57.
- Oka M, Noda Y, Ochi Y, et al. 1993. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J Pharmacol Exp Ther 264: 158–165.
- Osada K, Miyamoto S, Maruta S, et al. 2009. Long-term clinical study of blonanserin for schizophrenia: a multicenter open study to assess the safety and efficacy in patients with schizophrenia (continuation of two long-term studies by request from patients). Jpn J Clin Psychopharmacol 12: 2337–2351.
- Owen AM, Doyon J, Petrides M, et al. 1996. Planning and spatial working memory: a positron emission tomography study in humans. Eur J Neurosci 8: 353–364.
- Perkins DO, Gu H, Weiden PJ, et al. 2008. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 69: 106–113.
- Robinson D. 2010. First-episode schizophrenia. CNS Spectr 15: 4–7.
- Salimi K, Jarskog LF, Lieberman JA. 2009. Antipsychotic drugs for first-episode schizophrenia: a comparative review. CNS Drugs 23: 837–855.
- Saykin AJ, Shtasel DL, Gur RE, et al. 1994. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51: 124–131.
- Snitz BE, MacDonald A, 3rd, Cohen JD, et al. 2005. Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. Am J Psychiatry 162: 2322–2329.
- Sumiyoshi T, Bubenikova-Valesova V, Horacek J, et al. 2008. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. Adv Ther 25: 1037–1056.
- Tomida K, Takahashi N, Saito S, et al. 2010. Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin Neurosci 64: 62–69.
- van Veelen NM, Vink M, Ramsey NF, et al. 2010. Left dorsolateral prefrontal cortex dysfunction in medication-naive schizophrenia. Schizophr Res 123: 22–29.
- Velligan DI, Kern RS, Gold JM. 2006. Cognitive rehabilitation for schizophrenia and the putative role of motivation and expectancies. Schizophr Bull 32: 474–485.
- Wilkinson G, Hesdon B, Wild D, et al. 2000. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 177: 42–46.
- Wolwer W, Brinkmeyer J, Riesbeck M, et al. 2008. Neuropsychological impairments predict the clinical course in schizophrenia. Eur Arch Psychiatry Clin Neurosci 258(Suppl 5): 28–34.
- Woon PS, Chia MY, Chan WY, et al. 2010. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34: 463–468.
- Yang J, Bahk WM, Cho HS, et al. 2010. Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol 33: 169–175.
